Polycythemia Vera: Therapeutic Phlebotomy and Cytoreductive Management
All patients with polycythemia vera should initiate therapeutic phlebotomy immediately at diagnosis to maintain hematocrit below 45%, combined with daily low-dose aspirin. This recommendation is based on the landmark CYTO-PV trial demonstrating a nearly 4-fold reduction in cardiovascular death and major thrombotic events (HR 3.91) when maintaining hematocrit <45% versus 45-50% 1.
When to Initiate Phlebotomy
Phlebotomy should begin:
- Immediately at diagnosis for all PV patients, regardless of risk category
- As emergency therapy when patients present with very high hematocrit and hyperviscosity symptoms 2
- Induction phase: Remove 300-450 ml weekly or twice weekly until target hematocrit <45% is achieved 1
- Maintenance phase: Continue same volume removal at intervals determined by hematocrit monitoring 1
Cytoreductive Therapy Indications
Mandatory Cytoreduction (High-Risk Patients)
Cytoreductive therapy is strongly recommended for 1:
- Age >60 years
- Prior thrombotic event history
Additional Indications When Phlebotomy is Contraindicated or Problematic
Even in low-risk patients, cytoreduction should be initiated when 1:
- Poor phlebotomy tolerance (the most direct answer to contraindication)
- Symptomatic or progressive splenomegaly
- Severe disease-related symptoms
- Platelet count >1500 × 10⁹/L
- Leukocyte count >15 × 10⁹/L
- Severe iron deficiency with detrimental symptoms (pica, mouth paresthesia, esophagitis, restless legs) that worsens with iron supplementation
First-Line Cytoreductive Options
Either hydroxyurea or recombinant interferon-alpha (rIFNα) are the recommended first-line cytoreductive agents at any age 1.
Hydroxyurea
- Well-established efficacy and tolerance in most patients
- Caution in young patients: Use cautiously due to potential long-term leukemogenic risk (though evidence remains inconclusive) 2
- Preferred when rapid cytoreduction needed
Recombinant Interferon-Alpha (rIFNα)
- Particularly appropriate for younger patients
- Reduces JAK2V617F mutational burden
- Effective for aquagenic pruritus 2
- Newer pegylated formulations (ropeginterferon alfa-2b) have improved tolerability 3
Second-Line Cytoreductive Options
When patients are intolerant or resistant to first-line therapy 1:
Ruxolitinib (JAK1/JAK2 inhibitor)
- FDA-approved (2014) and EMA-approved (2015) for hydroxyurea-resistant or intolerant PV
- Effective for hematocrit control, splenomegaly reduction, and symptom management
- Both rIFNα and ruxolitinib are appropriate second-line options 1
Alternative Agents
- Anagrelide: For excessive thrombocytosis in conjunction with hydroxyurea 3
- Busulfan: Reserved as last resort in patients with limited life expectancy 3
Critical Management Algorithm
- All patients: Phlebotomy (target hematocrit <45%) + low-dose aspirin
- High-risk patients (age >60 or prior thrombosis): Add cytoreduction immediately
- Low-risk patients with phlebotomy contraindications/intolerance: Add cytoreduction
- First-line cytoreduction: Hydroxyurea OR rIFNα (prefer rIFNα in young patients)
- Second-line: Switch between hydroxyurea and rIFNα, or escalate to ruxolitinib
Important Caveats
- Cardiovascular risk factor management is mandatory in all patients 1
- The traditional binary risk stratification (age/thrombosis only) is increasingly recognized as inadequate; emerging markers include leukocytosis, neutrophil-to-lymphocyte ratio, and JAK2V617F variant allele frequency 4
- Iron supplementation should only be given for severe symptomatic iron deficiency, and if it worsens hematocrit, cytoreduction becomes necessary 1
- Extreme thrombocytosis (≥1000 × 10⁹/L) increases bleeding risk via acquired von Willebrand disease 5